Trial Profile
A Phase I Study of the Treatment of Recurrent Primary or Secondary CNS Lymphoma With ALIMTA (Pemetrexed), a Novel Anti-Folate.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Cobalamin; Dexamethasone; Filgrastim; Folic acid
- Indications B-cell lymphoma; CNS cancer
- Focus Adverse reactions
- 01 May 2020 Results (n=14; as of 1 Oct 2015) were presented at the 72nd Annual Meeting of the American Academy of Neurology
- 22 Sep 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 22 Oct 2013 Planned number of patients changed from 49 to 30 as reported by ClinicalTrials.gov.